Serum Amyloid A in lung transplantation

BACKGROUND: Serum Amyloid A (SAA) is an acute phase protein and we analyzed its concentrations in lung transplantated patients (LTX). METHODS: 26 LTX patients (58.6 ± 11 years) and 11 healthy controls (55 ± 11.3 years). Three groups of LTX patients: acute rejection (AR, 7) bronchiolitis obliterans s...

Descripción completa

Detalles Bibliográficos
Autores principales: Vietri, Lucia, Bargagli, Elena, Bennett, David, Fossi, Antonella, Cameli, Paolo, Bergantini, Laura, d’Alessandro, Miriana, Paladini, Piero, Luzzi, Luca, Gentili, Francesco, Mazzei, Maria Antonietta, Spina, Donatella, Sestini, Piersante, Rottoli, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2020
Materias:
Original Article: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569538/
https://www.ncbi.nlm.nih.gov/pubmed/33093763
http://dx.doi.org/10.36141/svdld.v37i1.8775
Descripción
Sumario:BACKGROUND: Serum Amyloid A (SAA) is an acute phase protein and we analyzed its concentrations in lung transplantated patients (LTX). METHODS: 26 LTX patients (58.6 ± 11 years) and 11 healthy controls (55 ± 11.3 years). Three groups of LTX patients: acute rejection (AR, 7) bronchiolitis obliterans syndrome (BOS, 3), acute infection (INF, 9) and stable patients (NEG, 7). RESULTS: In LTX patients SAA concentrations were significantly increased, particularly in AR and INF. In LTX-AR patients were observed a correlation between SAA levels and peripheral CD4+ lymphocyte percentage (r=0.9, p<0.01) and a reverse correlation with FVC percentages (r -0.94, p=0.01). CONCLUSIONS: SAA may represent a potential biomarker of LTX acute complications, with a prognostic value in AR. (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (1): 2-7)

Ejemplares similares